Our group works within many areas of colorectal cancer research, but focuses mainly on the control and treatment of metastatic colorectal cancer. Our aim is to develop efficacious treatments for locally advanced and metastatic colorectal cancer. We aim to reach this target by merging the clinic and lab through transitional projects utilising strategies such as preclinical models, clinical cohort studies and clinical intervention trials. Through these projects, we further our understanding of the biology of cancer, the biomarkers that may predict disease or disease progression, and the efficacy of new drugs and therapies.
Please click on the links below to read more about our work:
Metastatic Colorectal Cancer:
- The Oslo CoMet Study
- Providing resected metastasis specimens from CRC patients with liver-confined disease treated at OUS throughout the HSØ health region
- Peritoneal and Lung Metastasis from Colorectal Cancer
- Bone Marrow Micrometastasis in Colorectal Cancer
- Determining the prognostic value of detecting DTC in bone marrow from CRC patients treated with curatively intended surgery
- MOC31PE immunotoxin as a targeted therapy for EpCAM positive peritoneal carcinomatosis from CRC (PC-CRC)
- Cure 4 PMP
- An International network of collaborators working with Pseudomyxoma peritonei (PMP)
- Supporting and stimulating the immune system during chemotherapy.
Locally Advanced Rectal Cancer:
- The Locally Advanced Rectal Cancer—Exfoliation of Cells Study
- The Locally Advanced Rectal Cancer—Radiation Response Prediction Study
- Pelvic Radiation and Vorinostat